Published in final edited form as:

Bioorg Med Chem. 2014 January 15; 22(2): 711–720. doi:10.1016/j.bmc.2013.12.028.

Identifying novel targets in renal cell carcinoma: Design and synthesis of affinity chromatography reagents

Muriel Bonnet^a, Jack U. Flanagan^{a,b}, Denise A. Chan^{c,†}, Amato J. Giaccia^c, and Michael P. Hay^{a,b,*}

^aAuckland Cancer Society Research Centre, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand ^bMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland, New Zealand ^cDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA

Abstract

Two novel scaffolds, 4-pyridylanilinothiazoles (PAT) and 3-pyridylphenylsulfonyl benzamides (PPB), previously identified as selective cytotoxins for von Hippel–Lindau-deficient Renal Carcinoma cells, were used as templates to prepare affinity chromatography reagents to aid the identification of the molecular targets of these two classes. Structure–activity data and computational models were used to predict possible points of attachment for linker chains. In the PAT class, Click coupling of long chain azides with 2- and 3-pyridylanilinothiazoleacetylenes gave triazole-linked pyridylanilinothiazoles which did not retain the VHL-dependent selectivity of parent analogues. For the PPB class, Sonogashira coupling of 4-iodo-(3-pyridylphenylsulfonyl)benzamide with a propargyl hexaethylene glycol carbamate gave an acetylene which was reduced to the corresponding alkyl 3-pyridylphenylsulfonylbenzamide. This reagent retained the VHL-dependent selectivity of the parent analogues and was successfully utilized as an affinity reagent.

Keywords

Click chemistry; Sonogashira cross coupling; Renal cell carcinoma; Von Hippel–Lindau factor; GLUT-1

1. Introduction

Identification of tumour-selective agents is a top priority in anticancer drug development. One approach is to leverage a genetic abnormality common to a particular tumour type and to identify agents that are selectively cytotoxic to tumour cells with this genetic abnormality. We recently used such a synthetic lethality approach^{1–3} to discover two novel chemotypes

*Corresponding author. Tel.: +64 9 923 6598; fax: +64 9 373 7502. m.hay@auckland.ac.nz (M.P. Hay).

[†]Present address: Department of Radiation Oncology, University of California at San Francisco, San Francisco, CA 94143, USA.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2013.12.028>.

that were selectively cytotoxic to Renal Cell Carcinoma (RCC) cells lacking the von Hippel Lindau factor (VHL) both in vitro and in vivo.^{4,5}

RCCs are refractory to standard chemo- and radiotherapy and advanced RCC has an extremely poor prognosis.⁶ Although new 'targeted' anti-angiogenic agents such as sunitinib and sorafenib have been approved for use against the highly vascularised advanced RCC, these agents provide limited efficacy and patients eventually relapse and succumb to their disease. Thus, there is still a cogent need for drugs with increased efficacy in the treatment of advanced RCC. Common to a majority of RCCs is the loss of function of the von Hippel-Lindau (VHL) tumour suppressor gene.⁷ The VHL protein regulates a variety of proteins,⁸ including the activity of the Hypoxia Inducible Factor (HIF) family of transcription factors, by targeting them for degradation. Loss of this control increases HIF activity and increases transcription of a wide range of genes.⁹ This genetic response mimics the impact of tumour hypoxia and promotes reprogramming of tumor metabolism, progression, invasion, and metastasis, resulting in an aggressive phenotype, poor prognosis and resistance to therapeutic agents,^{10,11} and so the VHL-deficient RCC cell line also provides a model of tumour cells under hypoxic stress.

The two chemotypes identified in our synthetic lethal screen, 4-pyridylanilinothiazoles (PAT) (**1**) and 3-pyridylphenylsulfonyl benzamides (PPB) (**2**) (Fig. 1) displayed selective cytotoxicity for VHL-deficient RCC4 cells compared to RCC/VHL VHL-proficient cells (Table 1) but displayed different phenotypic behaviour. In the first case, PAT cytotoxicity was independent of HIF-1 status. PAT compounds induced autophagy, as measured by LC3 immunostaining and Western blot analysis, and this led to cell death. Functional analysis of the activity of the PAT class using a yeast deletion pool implicated proteins involved in Golgi body processing as important in the induction of autophagy, but failed to unequivocally identify the target protein(s) of the PATs.⁴

In contrast, PPB cytotoxicity was dependent on HIF-1 status and resulted in necrotic cell death. The PPBs decreased glycolysis in a VHL-dependent manner and inhibited the uptake of glucose.⁵

Further development of these novel chemotypes into viable anticancer agents is critically dependent on the identification of the molecular target of action. In this study we report our synthetic efforts to use structure activity relationships (SAR), in combination with molecular design, to develop chemical biology tools suitable for use in an affinity chromatography approach¹² for target identification for both PAT and PPB chemotypes.

2. Molecular design

We expanded on the initial hit compound **1** and explored the SAR for the PAT chemotype to identify more potent and selective analogues, but were hampered in this by the lack of an identified molecular target.¹³ This handicap led us to use a comparative molecular field analysis (CoMFA) to determine possible bioactive conformations to aid our studies. We identified a positive steric contour (Fig. 2, green volume) adjacent to the pyridine ring as a potential feature for further analogue development and this feature was further explored,

along with the orientation of the thiazole B-ring and the roles of the heteroatom substituents, in a subsequent study.¹⁴ We used Suzuki–Miyaura and Sonogashira Pd-mediated cross coupling reactions and nucleophilic displacement reactions to prepare series of aryl-, alkynyl-, alkoxy- and alkylamino-substituted pyridines, respectively, to explore the steric and electronic contours adjacent to the pyridyl ring. Although we failed to improve the predictivity of the CoMFA model, we did identify several analogues with increased potency and/or selectivity to **1**. The CoMFA model predicts the 2- and 3-positions of the pyridine ring were the most favorable for functionalization with a variety of groups at these positions providing potent and selective compounds. Although, two acetylenic compounds displayed selectivity for VHL-negative cells, a lack of selectivity for higher homologues dissuaded us from using an acetylene linker. Either pyrazole or triazole groups in the 2-position provided similar or improved potency and selectivity compared to the parent **1** [IC₅₀ (RCC4) ca. 2 μ M, selectivity (RCC4VHL/RCC4), 6 to 30-fold]¹⁴ and suggested a ‘Click’¹⁵ strategy to incorporate a long chain linker suitable for affinity chromatography.

Our SAR studies on the PPB chemotype identified considerable steric tolerance at the 4-position of the phenyl sulfonamide¹⁶ These data suggested molecules with a long chain linker attached to this position may retain activity and may provide a plausible strategy for attachment of linkers required for affinity reagents. The overexpression of the facultative glucose transporter GLUT-1 in VHL-deficient RCC cells, combined with evidence for inhibition of glucose uptake, led us to consider the possibility that the cytotoxicity of the PPBs was mediated through an interaction with GLUT-1.⁵ We were able to use a homology model of GLUT-1¹⁷ to identify a binding mode consistent with the SAR (Fig. 3) and our approach to position a long chain linker at the 4-position.

3. Results

3.1. Chemistry

3.1.1. PAT synthesis—We elaborated the 2-acetylene PATs using ‘Click’ chemistry to generate a substituted triazole. We had previously demonstrated that Sonogashira cross coupling reaction of bromide **3** with TMS acetylene in the presence of PdCl₂(PPh₃)₂ and CuI as catalysts gave an intermediate silylacetylene which was deprotected to give acetylene **4** in 75% yield (Scheme 1). Formation of the benzyltriazole **5** from acetylene **4** and benzyl azide also proceeded in good yield. Incorporation of a long chain alkyl linker using Click chemistry was initially investigated for a BOC-protected aminohexylazide. Reaction of *tert*-butyl (6-azidohexyl)carbamate with acetylene **4** gave triazole **6** in 39% yield which was deprotected to give amine **7** suitable for loading onto beads using *N*-hydroxysuccinimide coupling chemistry. We also wished to incorporate a longer polyethylene glycol chain as a linker and used the commercially available 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine in a Click reaction with acetylene **4** to give triazole **8** in 20% yield.

We had shown the aminothiazole NH is necessary for biological activity and so designed an appropriate negative control (Scheme 1). Alkylation of bromide **3** with ethyl iodide in DMF gave **9** in 66% yield. Sonogashira cross coupling reaction with TMS acetylene using PdCl₂(PPh₃)₂ and CuI in DMF/NEt₃ gave, after deprotection of the TMS group using

potassium carbonate in THF/MeOH, the acetylene **10**. Click reaction with 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine gave triazole product **11** in 71% yield.

We also explored the positive steric contour adjacent to the pyridyl ring via the 3-pyridyl position, although this proved more challenging due to the low reactivity at this position. The 3-bromopyridyl analogue **12** underwent Sonogashira cross-coupling reaction with TMS acetylene with subsequent deprotection of the TMS group to give the 3-acetylene **13** in low (10–35%) yields (Scheme 2). In an alternative strategy, 3-bromopyridine **12** was converted to the corresponding 3-iodopyridine **14** by a copper-catalyzed halogen exchange reaction. Sonogashira reaction with the iodide **14** gave acetylene **13** in 52% yield. Since this route adds an additional step and the overall yield was not significantly higher, it was not adopted.

We had previously demonstrated Click reaction of 3-acetylene **13** with benzyl azide gave benzyl triazole **15** in 55% yield.¹⁴ In this instance, Click reaction of acetylene **13** with 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine using CuSO₄·5H₂O and sodium ascorbate at room temperature, or at 40 °C, gave no product. However, addition of tris(benzyltriazolyl)amine (TBTA) ligand¹⁸ and increased reaction temperature (60 °C) gave the triazole PAT derivative **16** in 20% yield.

A negative control was also prepared for the 3-pyridyl isomer based on the observation that N-alkylation of the aniline abolished activity against RCC4 cells.¹³ Alkylation of 3-bromopyridine **12** with ethyl iodide in DMF gave **17** in 60% yield. Sonogashira cross-coupling reaction with TMS acetylene and subsequent deprotection of the TMS group gave 3-acetylene **18** in 65% yield. Finally, Click reaction in the presence of the TBTA ligand at 60 °C gave triazole product **19** in 41% yield.

3.1.2. PPB synthesis—We were able to readily prepare the propargyl-PEG₆-carbamate **24**¹⁹ efficiently from commercially available hexaethylene glycol **20** (Scheme 3). Glycol **20** was selectively mono-mesylated using mesyl chloride in the presence of silver oxide. Treatment of the mesylate **21** with sodium azide gave azide **22** in 99% yield. Reduction of **22** gave the intermediate amine which was protected as the carbamate **23** in 80% yield. Reaction of alcohol **23** with propargyl bromide gave the acetylene **24**.

Condensation of the protected benzoic acid **25**²⁰ with 3-aminopyridine gave the amide **26** which was deprotected and coupled to 4-iodophenylsulfonyl chloride to give the iodide **28** (Scheme 4). Sonogashira coupling was used to attach long chain linkers to the PPB core structure. Thus, reaction of **28** with propargyl-PEG₆-carbamate **24** gave the protected acetylene **29** which was readily deprotected to give amine **30**. We also explored a more flexible linker with reduction of the acetylene **29** giving carbamate **31** which was deprotected to give amine **32**. The negative control reagent was prepared using a phenyl replacement for the 3-pyridyl moiety based on the previously determined SAR which demonstrates increased potency for 3-pyridyl analogues.¹⁶ Thus in a similar sequence, coupling of benzoic acid **25** with aniline gave the amide **33** which was deprotected and coupled with 4-iodophenylsulfonyl chloride to give iodide **35**. Sonogashira coupling with **24** gave the acetylene **36** which was reduced and deprotected to give amine **38**.

3.2. Biological assays

The potency and selectivity of the potential affinity reagents were evaluated in a XTT growth inhibition assay (as IC₅₀: the drug concentration over a 4 d exposure required to inhibit cell growth by 50%) in the RCC4 VHL negative and the RCC/VHL positive cell lines (Table 1) to identify reagents with sufficient selectivity for target identification studies. Unfortunately, addition of long chain triazole substituents at the 2-position of the PAT scaffold was accompanied by loss of selectivity (**7**) or loss of potency (**8** and **11**). This was mirrored for analogues with long chain amines at the 3-position (**16** and **19**) and these negative results halted our efforts with this class. In contrast, the PPB reagents **30** and **32** retained potency and selectivity, although somewhat attenuated, for the RCC4 cell line, whereas the negative control **38** was inactive as required. Compounds **32** and **38** were conjugated to Affigel-10 resins and used for affinity chromatography on RCC4 cell homogenates using antibodies against GLUT-1, GLUT-2 and GLUT-3 for identification.⁵ This demonstrated selective retention of GLUT-1 protein by reagent **32**, but not reagent **38**, confirming GLUT-1 as a molecular target of the PPB chemotype.

4. Discussion

One of the risks of using phenotypic screens for drug discovery is that a molecular target for any hits may not be apparent. Not only does this hinder the 'hit-to-lead' development of the class, it undermines any potential clinical development of the agents. Here we have attempted to design chemical biology tools to assist in the identification of two hits identified from the same phenotypic screen. The two classes of compound had quite different properties with the PAT class inducing cell death via autophagy in a VHL-dependent manner and the PPB class inducing necrotic cell death via disruption of glucose metabolism in a HIF-dependent manner. Our pursuit of chemical biology tools to tease out the molecular targets was guided by established SAR and interpretation using molecular modelling. The CoMFA model developed from the SAR of the PAT class had demonstrated a positive steric contour adjacent to the pyridyl ring, but attempts to exploit this putative space gave mixed results. Our efforts to build on analogues bearing pyrazole or triazole substituents at the 2-position were not successful and none of the reagents prepared for the PAT class showed any selectivity for VHL-negative cells. That the CoMFA model could account for only ca 34% of the variation in cytotoxicity data may contribute to our inability to identify PAT reagents with selectivity for VHL-deficient cells.

On the other hand we had accumulated evidence suggesting that glucose metabolism was the target process for the PPB class and this provided a limited number of molecular targets. This was further clarified through glucose uptake experiments which demonstrated that the PPB class did inhibit glucose uptake.⁵ The biochemical and genetic evidence suggested that GLUT-1 was a potential molecular target and this was confirmed using the PPB affinity chromatography reagents.⁵ Subsequently, we modelled a series of 'active' PPB analogues and the known GLUT-1 inhibitor fasentin²¹ in the transporter's central channel to explore potential interactions between the PPB scaffold and GLUT-1. The GLUT-1 homology model (PDB No. 1SUK) had been generated using the glycerol 3-phosphate antiporter GlpT structure as an initial homology template followed by evolutionary homology using

glucose-6-phosphate translocase as a template. The resulting structure accounted for the biochemical and mutagenic evidence, as well as identifying binding sites for glucose and several inhibitors.²¹ The active compounds (S1–S6; Supporting Information) were selected from those displaying <1 μM IC₅₀ values against the RCC4 cell line and a selectivity for the RCC4 over the RCC4/VHL cell line of >100. Some predicted binding modes positioned the 3-pyridyl moiety deep into the central channel towards the extracellular end, occupying a position similar to that predicted for fasentin (Fig. 3). In this orientation, the amide carbonyl group occupies a similar location to amide carbonyl in fasentin, with both groups potentially able to interact with the side chain of Arg126, a residue involved in glucose transport.²² In this mode, the ligand's central aromatic group is located between the channel aromatic residues Tyr28, Phe72 and Trp412. Additionally, the sulfonyl group may also interact with the indole nitrogen of Trp412, another residue associated with glucose transport.²³ The various substituents at the 4-phenyl position were oriented toward the intracellular entrance of the channel, and the tolerance observed for various substituents provides the rationale for appending a long chain linker group at the 4-phenyl position. Other predicted binding modes indicated the potential for an interaction between the ligands pyridyl N and the side chain amine of Lys38. Such an interaction may explain loss of potency and selectivity seen for the phenyl derivative **38**. Although the side chain positions were not optimized for ligand binding in the GLUT1 homology model, the data indicate the potential for the active compounds to interact with several key residues that span the solute channel. The proposed binding mode appears to occupy a similar site predicted for both the recently reported thiazolidine 2,4-diones²⁴ and diphenoxybenzoates^{25–27} that inhibit glucose uptake through binding to GLUT-1. In particular, the thiazolidine 2,4-diones are predicted to make an electrostatic interaction with Trp412 and Arg126 as well as form a π – π stacking interaction with Tyr28²⁴. Similarly, the diphenoxybenzoate WZB114 was modelled binding to Arg126 and Trp412, as well as Asn34. While these interactions remain to be formally tested, it is possible that the hydrophobic and polar groups contributed by these amino acids define a tractable drug target within the solute channel of GLUT-1, and these may provide an opportunity for the identification of new GLUT-1 inhibitors.

This study highlights the successful design and synthesis of chemical biology tools to identify the molecular target of the PPB class, while also showing that success in these endeavours is not always guaranteed. Having identified the molecular target of the PPBs we are now poised to further develop this class towards a tumour-selective anti-tumour agent. The potential opportunity afforded by these agents is increasingly recognised as a novel therapeutic strategy for the treatment of cancer.^{28,29}

5. Experimental

5.1. Chemistry

5.1.1. General procedures—Analyses were carried out in the Campbell Microanalytical Laboratory, University of Otago, Dunedin, NZ. All final products were analysed by reverse-phase HPLC, (Altima C18 5 μm column, 150 $\times$ 3.2 mm; Alltech Associated, Inc., Deerfield, IL) using an Agilent HP1100 equipped with a diode-array detector. Mobile phases were gradients of 80% acetonitrile/20% H₂O (v/v) in 45 mM ammonium formate at pH 3.5 and

0.5 mL/min. Final compound purity was determined by monitoring at 330 ± 50 nM and was >95%. Melting points were determined on an Electrothermal 2300 Melting Point Apparatus. NMR spectra were obtained on a Bruker Avance 400 spectrometer at 400 MHz for ^1H and 100 MHz for ^{13}C spectra. Spectra were obtained in $(\text{CD}_3)_2\text{SO}$ unless otherwise specified, and were referenced to Me_4Si . Chemical shifts and coupling constants were recorded in units of ppm and Hz, respectively. Assignments were determined using COSY, HSQC, and HMBC two-dimensional experiments. Low resolution mass spectra were gathered by direct injection of methanolic solutions into a Surveyor MSQ mass spectrometer using an atmospheric pressure chemical ionization (APCI) mode with a corona voltage of 50 V and a source temperature of 400 °C. High resolution mass spectra (HRMS) were measured on a Bruker microTOF-QII Hybrid Quadrupole Time of Flight (TOF-Q) mass spectrometer interfaced with either an Electrospray Ionization (ESI) or Atmospheric Pressure Chemical Ionization (APCI) probe allowing positive or negative ions detection. Solutions in organic solvents were dried with anhydrous MgSO_4 . Solvents were evaporated under reduced pressure on a rotary evaporator. Thin-layer chromatography was carried out on aluminium-backed silica gel plates (Merck 60 F₂₅₄) with visualization of components by UV light (254 nm) or exposure to I_2 . Column chromatography was carried out on silica gel (Merck 230–400 mesh).

Compounds **3**, **4**, **5**, **12**, **13**, **14** and **15** were prepared as previously described.^{14,15}

5.1.2. *tert*-Butyl 6-(4-{4-[2-(3-toluidino)-1,3-thiazol-4-yl]-2-pyridinyl}-1*H*-1,2,3-triazol-1-yl)hexylcarbamate (6)— $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (16 mg, 0.064 mmol) and sodium ascorbate (26 mg, 0.13 mmol) were added to a solution of acetylene **4** (185 mg, 0.64 mmol) and *tert*-butyl 6-azidoethylcarbamate (160 mg, 0.70 mmol) in a mixture of DCM/ H_2O /EtOH (1:1:1, 3 mL). The reaction was stirred at 18 °C for 24 h and was then partitioned between EtOAc (150 mL) and H_2O (50 mL). The organic phase was washed with H_2O (2×10 mL), dried and the solvent was evaporated. The residue was purified by column chromatography, eluting with 2% MeOH/DCM, to give triazole **6** (140 mg, 42%) as a colourless viscous oil: ^1H NMR δ 10.31 (s, 1H, NH), 8.62–8.63 (m, 2H, H-5', H-6''), 8.54 (dd, $J = 1.6, 0.7$ Hz, 1H, H-3''), 7.80 (dd, $J = 5.1, 1.6$ Hz, 1H, H-5''), 7.79 (s, 1H, H-5'''), 7.57 (br s, 1H, H-2''), 7.51 (br d, $J = 8.1$ Hz, 1H, H-6''), 7.25 (t, $J = 7.8$ Hz, 1H, H-5''), 6.83 (d, $J = 7.4$ Hz, 1H, H-4''), 6.72 (br s, 1H, NHBoc), 4.43 (t, $J = 7.0$ Hz, 2H, H-6), 2.89 (q, $J = 6.3$ Hz, 2H, H-1), 2.35 (s, 3H, CH_3), 1.84–1.92 (m, 2H, CH_2), 1.36 [s, 11H, $\text{C}(\text{CH}_3)_3$, CH_2], 1.27–1.28 (m, 4H, CH_2); ^{13}C NMR δ 163.6, 155.5, 150.8, 150.1, 147.6, 147.2, 142.0, 140.9, 138.2, 128.9, 123.2, 122.3, 118.9, 117.7, 115.5, 114.2, 107.7, 77.3, 49.5, 29.6, 29.2, 28.2 (3), 25.6, 25.5, 21.3 (1C not observed); MS m/z 535.5 (MH^+ , 100%). Anal. Calcd for $\text{C}_{28}\text{H}_{35}\text{N}_7\text{O}_2 \cdot \frac{1}{3}\text{H}_2\text{O}$: C, 62.31; H, 6.66; N, 18.17. Found: C, 62.39; H, 6.55; N, 17.94.

5.1.3. 6-(4-{4-[2-(3-Methylphenyl)-1,3-thiazol-4-yl]-2-pyridinyl}-1*H*-1,2,3-triazol-1-yl)-1-hexan ammonium trifluoroacetate (7)—TFA (0.44 mL, 5.8 mmol) was added to a solution of carbamate **6** (125 mg, 0.23 mmol) in DCM (15 mL), and the reaction mixture was stirred at 18 °C for 3 h. The solvent was evaporated and the residue was dried under high vacuum. The residue was triturated with tPr_2O , filtered and dried to give the trifluoroacetate salt **7** (130 mg, 100%) as an orange solid: mp (tPr_2O) 179–181 °C; ^1H NMR

δ 10.33 (s, 1H, NH), 8.68 (s, 1H, H-5'''), 8.64 (br d, J = 5.3 Hz, 1H, H-6''), 8.57 (d, J = 0.9 Hz, 1H, H-3''), 7.85 (dd, J = 5.3, 1.7 Hz, 1H, H-5''), 7.84 (s, 1H, H-5), 7.67 (br s, 3H, NH₃), 7.58 (br s, 1H, H-2'), 7.51 (br d, J = 8.1 Hz, 1H, H-6'), 7.25 (t, J = 7.8 Hz, 1H, H-5'), 6.83 (d, J = 7.5 Hz, 1H, H-4'), 4.47 (t, J = 6.9 Hz, 2H, H-1''); ¹³C NMR δ 163.7, 158.1 (q, J = 35.0 Hz), 150.1, 149.5, 147.4, 146.6, 142.6, 140.9, 138.3, 128.9, 123.5, 122.4, 119.1, 117.7, 115.7, 114.3, 108.4, 49.5, 29.3, 26.7, 25.3, 25.1 (2), 21.3; MS m/z 435.2 (MH⁺, 100%).
 Anal. Calcd for C₂₈H₃₅N₇O₂S·2.25CF₃CO₂H: C, 47.86; H, 4.27; N, 14.21. Found: C, 47.98; H, 4.37; N, 14.13.

5.1.4. 4-{2-[1-(20-Amino-3,6,9,12,15,18-hexaoxaicos-1-yl)-1*H*-1,2,3-triazol-4-yl]-4-pyridinyl}-*N*-(3-methylphenyl)-1,3-thiazol-2-amine (8)—CuSO₄·5H₂O (5 mg, 0.02 mmol) and sodium ascorbate (8 mg, 0.04 mmol) were added to a suspension of acetylene **4** (50 mg, 0.17 mmol) and 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine (60 mg, 0.17 mmol) in a mixture of DCM/H₂O/EtOH (1:1:1; 1.5 mL), and the reaction mixture was stirred at 18 °C for 20 h. The mixture was then diluted with EtOAc (100 mL) and washed with H₂O (3 × 10 mL), washed with brine (10 mL), dried and the solvent was evaporated. The residue was purified by column chromatography, eluting with 0.5% NH₄OH/1.5% MeOH/EtOAc, to give triazole **8** (20 mg, 18%) as a tan glass: ¹H NMR δ 10.32 (br s, 1H, NH), 8.63 (dd, J = 5.2, 0.6 Hz, 1H, H-6''), 8.58 (s, 1H, H-5'''), 8.55 (dd, J = 1.6, 0.7 Hz, 1H, H-3''), 7.78–7.81 (m, 2H, H-5, H-5''), 7.58 (s, 1H, H-2'), 7.50 (br d, J = 8.1 Hz, 1H, H-6'), 7.25 (t, J = 7.8 Hz, 1H, H-5'), 6.83 (d, J = 7.5 Hz, 1H, H-4'), 6.62 (br s, 2H, NH₂), 4.63 (t, J = 5.2 Hz, 2H, H-1), 3.90 (t, J = 5.2 Hz, 2H, H-2), 3.56 (m, 2H, OCH₂), 3.49–3.52 (m, 2H, OCH₂), 3.44–3.48 (m, 16 H, OCH₂), 3.33 (t, J = 5.8 Hz, 2H, H-19), 2.63 (br t, J = 5.4 Hz, 2H, H-20), 2.35 (s, 3H, CH₃); ¹³C NMR δ 163.6, 150.7, 150.1, 147.6, 147.2, 142.0, 140.9, 138.2, 128.9, 123.7, 122.3, 118.9, 117.7, 115.5, 114.2, 107.7, 72.8, 69.7 (2), 69.7 (4), 69.6 (2), 69.5 (2), 68.6, 49.6, 41.2, 21.3; MS m/z 642.1 (MH⁺, 100%); HRMS (ESI) Calcd for C₃₁H₄₄N₇O₆S (MH⁺) m/z 642.3068; found m/z 642.3067.

5.1.5. 4-(2-Bromo-4-pyridinyl)-*N*-ethyl-*N*-(3-methylphenyl)-1,3-thiazol-2-amine (9)—K₂CO₃ (97 mg, 0.7 mmol) and EtI (56 μ L, 0.7 mmol) were added to a stirred solution of bromopyridine **3** (200 mg, 0.58 mmol) in anhydrous DMF (3 mL) and the reaction mixture was stirred at 18 °C for 20 h. The mixture was partitioned between EtOAc (100 mL) and H₂O (50 mL). The organic phase was washed with H₂O (3 × 20 mL), brine (20 mL), dried and the solvent was evaporated. The residue was purified by column chromatography, eluting with 20% EtOAc/pet. ether, to give amine **9** (142 mg, 66%) as a colourless oil which was used directly: ¹H NMR δ 8.38 (dd, J = 5.1, 0.4 Hz, 1H, H-6'), 8.02 (d, J = 0.8 Hz, 1H, H-3''), 7.85 (dd, J = 5.1, 1.4 Hz, 1H, H-5''), 7.64 (s, 1H, H-5), 7.40 (t, J = 7.7 Hz, 1H, H-5'), 7.29 (br s, 1H, H-2'), 7.26 (br d, J = 7.8 Hz, 1H, H-6'), 7.20 (br d, J = 7.5 Hz, 1H, H-4'), 4.02 (q, J = 7.1 Hz, 2H, CH₂CH₃), 2.36 (s, 3H, CH₃), 1.22 (t, J = 7.1 Hz, 3H, CH₂CH₃); MS m/z 374.8/376.8 (MH⁺, 100%).

5.1.6. *N*-Ethyl-4-(2-ethynyl-4-pyridinyl)-*N*-(3-methylphenyl)-1,3-thiazol-2-amine (10)—PdCl₂(PPh₃)₂ (21 mg, 0.03 mmol) was added to a purged solution of bromopyridine **9** (203 mg, 0.54 mmol), TMS-acetylene (0.43 mL, 3.0 mmol), and CuI (6 mg, 0.03 mmol) in a mixture of DMF and NEt₃ (1:1; 4 mL), and the reaction mixture was stirred at 50 °C for 2 h.

The reaction mixture was cooled to 18 °C, and partitioned between EtOAc (200 mL) and H₂O (50 mL). The organic phase was washed with brine (50 mL), dried and the solvent was evaporated. The residue was dissolved in a mixture of THF/MeOH (1:1; 20 mL), K₂CO₃ (75 mg, 0.54 mmol) was added and the mixture was stirred at 18 °C for 1 h. The solvent was evaporated and the residue purified by column chromatography, eluting with 20% EtOAc/pet. ether, to give acetylene **10** (145 mg, 84%) as a colourless oil which was used directly: ¹H NMR δ 8.56 (dd, *J* = 5.2, 0.7 Hz, 1H, H-6''), 7.96 (dd, *J* = 1.6, 0.7 Hz, 1H, H-3''), 7.82 (dd, *J* = 5.2, 1.7 Hz, 1H, H-5''), 7.59 (s, 1H, H-5), 7.39 (t, *J* = 7.7 Hz, 1H, H-5'), 7.29 (br s, 1H, H-2'), 7.25 (br d, *J* = 7.7 Hz, 1H, H-6'), 7.19 (br d, *J* = 7.6 Hz, 1H, H-4'), 4.32 (s, 1H, C≡CH), 4.03 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 2.35 (s, 3H, CH₃), 1.22 (t, 3H, CH₂CH₃); ¹³C NMR δ 169.2, 150.6, 147.0, 144.0, 142.2, 141.9, 139.7, 129.9, 128.2, 127.1, 123.8, 123.3, 119.8, 107.7, 83.3, 80.0, 47.2, 20.8, 12.7; MS *m/z* 320.7 (MH⁺, 100%).

5.1.7. 4-{2-[1-(20-Amino-3,6,9,12,15,18-hexaoxaicos-1-yl)-1*H*-1,2,3-triazol-4-yl]-4-pyridinyl}-*N*-ethyl-*N*-(3-methylphenyl)-1,3-thiazol-2-amine (11**)—**

CuSO₄·5H₂O (10 mg, 0.04 mmol) and sodium ascorbate (16 mg, 0.08 mmol) were added to a suspension of acetylene **10** (120 mg, 0.37 mmol) and 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine (72 mg, 0.21 mmol) in a mixture of DCM/H₂O/EtOH (1:1:1; 3 mL), and the reaction mixture was stirred at 18 °C for 20 h. The mixture was diluted with 20% MeOH/DCM (100 mL), SiO₂ was added and the solvent was evaporated. The residue was purified by column chromatography, eluting with 0.5% NH₄OH (28%)/1.5% MeOH/EtOAc, to give triazole **11** (90 mg, 71%) as a tan oil: ¹H NMR δ 8.59 (dd, *J* = 5.2, 0.7 Hz, 1H, H-6''), 8.58 (s, 1H, H-5'''), 8.46 (dd, *J* = 1.6, 0.7 Hz, 1H, H-3''), 7.74 (dd, *J* = 5.2, 1.7 Hz, 1H, H-5''), 4.58 (s, 1H, H-5), 7.40 (t, *J* = 7.7 Hz, 1H, H-5'), 7.31 (br s, 1H, H-2'), 7.27 (br d, *J* = 7.8 Hz, 1H, H-6'), 7.20 (br d, *J* = 7.6 Hz, 1H, H-4'), 4.62 (t, *J* = 5.2 Hz, 2H, H-1''), 4.07 (q, *J* = 7.0 Hz, 2H, CH₂CH₃), 3.89 (t, *J* = 5.2 Hz, 2H, H-2''), 3.56 (m, 2H, OCH₂), 3.45–3.51 (m, 18 H, OCH₂), 3.34 (t, *J* = 5.8 Hz, 2H, H-19''), 2.64 (t, *J* = 5.8 Hz, 2H, H-20''), 2.36 (s, 3H, CH₃), 1.25 (t, *J* = 7.0 Hz, 3H, CH₂CH₃), NH₂ not observed; ¹³C NMR δ 169.2, 150.7, 150.0, 147.9, 147.2, 144.1, 142.2, 139.7, 129.8, 128.1, 127.1, 123.75, 123.71, 119.0, 115.4, 107.1, 72.8, 69.73 (3), 69.72 (4), 69.6 (2), 69.5, 68.6, 49.6, 47.1, 41.2, 20.8, 12.8; MS *m/z* 672.4 (MH⁺, 100%); HRMS Calcd for C₃₃H₄₈N₇O₆S (MH⁺) *m/z* 670.3381; found *m/z* 670.3394.

5.1.8. 20-(4-{4-[2-(3-Methylphenyl)-1,3-thiazol-4-yl]-3-pyridinyl}-1*H*-1,2,3-triazol-1-yl)-3,6,9,12,15,18-hexaoxaicosan-1-ammonium trifluoroacetate (16**)—**

CuSO₄·5H₂O (4 mg, 0.09 mmol), sodium ascorbate (6 mg, 0.03 mmol) and TBTA (16 mg, 0.03 mmol) were added to a suspension of acetylene **13** (42 mg, 0.15 mmol) and 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine (32 mg, 0.09 mmol) in a mixture of DMF/H₂O (1:1; 2 mL) and the reaction mixture was stirred at 18 °C for 3 h and then at 60 °C for 16 h. Additional acetylene **13** (30 mg, 0.1 mmol) in DCM (1 mL) was added and the mixture was heated at 60 °C for 1 h, at which time all the starting azide has been consumed. The reaction mixture was diluted with MeOH (15 mL), SiO₂ (1 g) was added and the solvent was evaporated. The residue was purified by column chromatography, eluting with 0.5% aq NH₃ (25%)/1.5% MeOH/EtOAc, to give crude amine **16** (35 mg, 66%). The product was further purified by reverse phase preparative HPLC [gradient (90–2–90%)

(H₂O/TFA pH 2.56)/(90% CH₃CN/H₂O)] to give amine **16** as the trifluoroacetate salt (18 mg, 26%) as a tan oil: ¹H NMR δ 10.19 (s, 1H, NH), 8.84 (s, 1H, H-2''), 8.69 (d, *J* = 5.1 Hz, 1H, H-6''), 7.99 (s, 1H, H-5'), 7.83 (d, *J* = 5.2 Hz, 1H, H-5''), 7.74 (br s, 3H, NH₃⁺), 7.23–7.26 (m, 2H, H-2''', H-6'''), 7.13 (t, *J* = 7.7 Hz, 1H, H-5'''), 6.98 (s, 1H, H-5'''), 6.75 (d, *J* = 7.4 Hz, 1H, H-4'''), 4.48 (t, *J* = 5.3 Hz, 2H, H-20), 3.70 (t, *J* = 5.3 Hz, 2H, H-19), 3.58 (t, *J* = 5.3 Hz, 2H, H-2), 3.42–3.56 (m, 20 H, 10 × CH₂O), 2.97 (sext, *J* = 5.5 Hz, 2H, H-1), 2.24 (s, 3H, CH₃); ¹³C NMR δ 162.9, 149.1, 147.9, 146.8, 142.4, 141.9, 140.8, 138.1, 128.7, 124.8, 122.1, 117.3, 114.0, 109.7, 69.69 (8), 69.66 (2), 69.6, 69.55, 69.53, 68.5, 66.6, (2C not observed); MS *m/z* 642.1 (MH⁺, 100%); HRMS (ESI) Calcd for C₃₁H₄₄N₇O₆S (MH⁺) *m/z* 642.3068; found *m/z* 642.3071.

5.1.9. 4-(3-Bromo-4-pyridinyl)-*N*-ethyl-*N*-(3-methylphenyl)-1,3-thiazol-2-amine

(17)—EtI (56 μL, 0.7 mmol) was added to a mixture of bromopyridine **12** (200 mg, 0.58 mmol) and K₂CO₃ (97 mg, 0.7 mmol) in anhydrous DMF and the reaction mixture was stirred at 18 °C for 20 h. The mixture was partitioned between EtOAc (150 mL) and H₂O (50 mL). The organic layer was washed with H₂O (50 mL) washed with brine (50 mL), dried and the solvent was evaporated. The residue was purified by column chromatography, eluting with 20% EtOAc/pet. ether, to give the amine **17** (130 mg, 60%) as a colourless oil: ¹H NMR δ 8.79 (s, 1H, H-2''), 8.58 (d, *J* = 5.0 Hz, 1H, H-6''), 7.87 (br d, *J* = 5.1 Hz, 1H, H-5''), 7.49 (s, 1H, H-5), 7.39 (t, *J* = 7.7 Hz, 1H, H-5'), 7.30 (br s, 1H, H-2'), 7.27 (br d, *J* = 7.8 Hz, 1H, H-6'), 7.19 (br d, *J* = 7.5 Hz, 1H, H-4'), 3.99 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 2.36 (s, 3H, CH₃), 1.22 (t, *J* = 7.1, 3H, CH₂CH₃); ¹³C NMR δ 163.3, 152.7, 148.6, 145.8, 144.2, 141.5, 139.8, 129.9, 128.1, 127.0, 125.1, 123.6, 118.1, 110.0, 47.3, 20.8, 12.8; MS *m/z* 376.0 (MH⁺, 100%), HRMS (ESI) Calcd for C₁₇H₁₇BrN₃S (MH⁺) *m/z* 374.0321; found *m/z* 374.0324.

5.1.10. *N*-Ethyl-4-(3-ethynyl-4-pyridinyl)-*N*-(3-methylphenyl)-1,3-thiazol-2-amine

(18)—PdCl₂(PPh₃)₂ (30 mg, 0.04 mmol) was added to a purged solution of bromopyridine **17** (130 mg, 0.35 mmol), TMS-acetylene (0.5 mL, 3.5 mmol), and CuI (8 mg, 0.04 mmol) in a mixture of DMF/NEt₃ (1:1; 4 mL), and the reaction mixture was stirred at 50 °C for 2 h. The mixture was cooled to 18 °C and was partitioned between EtOAc (200 mL) and H₂O (50 mL). The organic phase was washed with brine (50 mL), dried and the solvent was evaporated. The residue was dissolved in a mixture of THF/MeOH (1:1; 30 mL), K₂CO₃ (50 mg, 0.35 mmol) was added and the mixture was stirred at 18 °C for 1 h. The solvent was then evaporated and the residue purified by column chromatography, eluting with 20% EtOAc/pet. ether, to give acetylene **18** (72 mg, 65%) as an unstable yellow oil which was used without further purification: ¹H NMR δ 8.74 (s, 1H, H-2''), 8.57 (d, *J* = 5.1 Hz, 1H, H-6''), 8.04 (d, *J* = 5.3 Hz, 1H, H-5''), 7.76 (s, 1H, H-5), 7.34 (dt, *J* = 7.4, 1.1 Hz, 1H, H-5'), 7.19 (br s, 1H, H-2'), 7.14–7.19 (m, 2H, H-4', H-6'), 4.07 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 3.47 (s, 1H, C≡CH), 2.39 (s, 3H, CH₃), 1.31 (t, *J* = 7.1 Hz, 3H, CH₂CH₃); MS *m/z* 320.7 (MH⁺, 100%).

5.1.11. 20-(4-{4-[2-(Ethyl-3-methylanilino)-1,3-thiazol-4-yl]-3-pyridinyl}-1*H*-1,2,3-triazol-1-yl)-3,6,9,12,15,18-hexaoxaicosan-1-ammonium trifluoroacetate

(19)—CuSO₄·5H₂O (6 mg, 0.022 mmol), sodium ascorbate (10 mg, 0.044 mmol) and TBTA (25

mg, 0.044 mmol) were added to a suspension of acetylene **18** (71 mg, 0.22 mmol) and 20-azido-3,6,9,12,15,18-hexaoxaicosan-1-amine (80 mg, 0.22 mmol) in a mixture of DMF, DCM and H₂O (1:1:1; 3 mL), and the mixture was heated at 50 °C for 3 h. The reaction mixture was cooled to 18 °C, diluted with DCM and MeOH (30 mL), SiO₂ (1 g) was added and the solvent was evaporated. The residue was purified by column chromatography, eluting with 0.5% aq NH₃ (25%)/1.5% MeOH/EtOAc, to afford crude amine **19** (90 mg). The product was further purified by preparative HPLC [gradient (95–64%) (H₂O/TFA pH 2.56)/(90% CH₃CN/H₂O)] to give the amine **19** as the trifluoroacetate salt (60 mg, 41%) as a tan oil: ¹H NMR δ 8.81 (s, 1H, H-2''), 8.69 (d, *J* = 5.4 Hz, 1H, H-6''), 8.09 (s, 1H, H-5'), 7.89 (d, *J* = 5.4 Hz, 1H, H-5''), 7.75 (br s, 3H, NH₃⁺), 7.37 (t, *J* = 7.7 Hz, 1H, H-5''), 7.25 (br s, 1H, H-2''), 7.22 (br d, *J* = 7.9 Hz, 1H, H-6''), 7.17 (br d, *J* = 7.6 Hz, 1H, H-4''), 6.73 (s, 1H, H-5''), 4.58 (t, *J* = 5.2 Hz, 2H, H-20), 3.86 (q, *J* = 7.1 Hz, 2H, CH₂CH₃), 3.84 (t, *J* = 5.2 Hz, 2H, H-19), 3.58 (t, *J* = 5.3 Hz, 2H, H-2), 3.42–3.56 (m, 20 H, 10 × CH₂O), 2.97 (sext, *J* = 5.5 Hz, 2H, H-1), 2.34 (s, 3H, CH₃), 1.11 (t, *J* = 7.1 Hz, 3H, CH₂CH₃); ¹³C NMR δ 168.5, 158.2 (q, *J* = 36 Hz), 148.4, 147.2, 146.7, 144.1, 142.8, 142.2, 139.7, 129.8, 128.0, 126.9, 125.2, 124.8, 124.2, 123.6, 115.8 (q, *J* = 292 Hz), 109.7, 69.69 (4), 69.67 (3), 69.59 (2), 69.56, 68.6, 66.6, 49.5, 47.2, 38.6, 20.8, 12.6; MS *m/z* 672.4 (MH⁺, 100%); HRMS (ESI) Calcd for C₃₃H₄₈N₇O₆S (MH⁺) *m/z* 670.3381; found *m/z* 670.3349.

5.1.12. *tert*-Butyl 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-ylcarbamate (**23**)

—Mesyl chloride (1.78 mL, 23.0 mmol) was added dropwise to a stirred suspension of hexaethylene glycol **20** (5.42 g, 19.2 mmol) and Ag₂O (4.67 g, 20.2 mmol) in dry DCM (50 mL) at 20 °C and the mixture was stirred at 20 °C for 3 days. The mixture was filtered through diatomaceous earth and the solvent evaporated. The residue was purified by column chromatography, eluting with a gradient (0–10%) of MeOH/EtOAc, to give 17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl methanesulfonate (**21**) (3.52 g, 51%) as a colourless oil: ¹H NMR (CDCl₃) δ 4.36–4.40 (m, 2H, CH₂OSO₂), 3.76–3.78 (m, 2H, CH₂O), 3.70–3.74 (m, 2H, CH₂O), 3.64–3.67 (m, 16 H, 8 × CH₂O), 3.59–3.62 (m, 2H, CH₂O), 3.09 (s, 3H, SO₂CH₃), 2.80 (br s, 1H, OH); MS *m/z* 361.6 (MH⁺, 100%). A mixture of the mesylate **21** (3.52 g, 9.8 mmol) and NaN₃ (1.27 g, 19.5 mmol) in dry DMF (20 mL) was stirred at 110 °C for 2 h. The mixture was cooled to 20 °C and the solvent evaporated. The residue was purified by column chromatography, eluting with 10% MeOH/EtOAc, to give 17-azido-3,6,9,12,15-pentaoxaheptadecan-1-ol (**22**) (2.98 g, 99%) as a colourless oil: ¹H NMR (CDCl₃) δ 3.71–3.74 (m, 2H, CH₂O), 3.65–3.69 (m, 18 H, 9 × CH₂O), 3.59–3.62 (m, 2H, CH₂O), 3.39 (br t, *J* = 5.2 Hz, 2H, CH₂N₃), 2.82 (br s, 1H, OH); MS *m/z* 308.5 (MH⁺, 100%). A mixture of azide **22** (2.98 g, 9.7 mmol) and Pd/C (100 mg) in EtOH (50 mL) was stirred under H₂ (60 psi) for 1 h. The mixture was filtered through diatomaceous earth and washed with EtOH (3 × 20 mL) and the solvent was evaporated. The crude residue was dissolved in DCM (50 mL) and di-*tert*-butyl dicarbonate (2.56 g, 11.7 mmol) in DCM (20 mL) was added dropwise and the solution was stirred at 20 °C for 16 h. The solvent was evaporated and residue was purified by column chromatography, eluting with 10% MeOH/EtOAc, to give carbamate **23** (2.97 g, 80%) as a colourless oil: ¹H NMR (CDCl₃) δ 5.17 (br s, 1H, NHCO₂), 3.70–3.74 (m, 2H, CH₂O), 3.60–3.68 (m, 18 H, 9 × CH₂O), 3.54 (br t, *J* =

5.1 Hz, 2H, CH₂O), 3.31 (br q, J = 5.1 Hz, 2H, CH₂N), 2.81 (br s, 1H, OH), 1.44 [s, 9 H, C(CH₃)₃]; MS m/z 382.5 (MH⁺, 100%).

5.1.13. *tert*-Butyl 3,6,9,12,15,18-hexaoxahenicos-20-yn-1-ylcarbamate (24)—

NaH (343 mg, 8.56 mmol) was added in small portions to a stirred solution of alcohol **15** (2.97 g, 7.8 mmol) in THF (50 mL) at 0 °C and the resulting mixture stirred at 0 °C for 30 min. Propargyl bromide (0.87 mL, 7.8 mmol) was added followed by nBu₄N⁺I[−] (29 mg, 78 μmol) and the mixture was stirred at 20 °C for 16 h. The reaction was quenched with satd aq NH₄Cl and extracted with EtOAc (4 × 50 mL). The combined organic fraction was washed with brine (50 mL), dried and the solvent evaporated. The residue was purified by column chromatography, eluting with 80% EtOAc/pet. ether, to give the acetylene **24** (2.56 g, 79%) as a colourless oil: ¹H NMR (CDCl₃) δ 5.05 (br s, 1H, NHCO₂), 4.20 (d, J = 2.4 Hz, 2H, CH₂C≡C), 3.68–3.71 (m, 4H, 2 × CH₂O), 3.64–3.67 (m, 12H, 6 × CH₂O), 3.60–3.63 (m, 4H, 2 × CH₂O), 3.54 (br t, J = 5.2 Hz, 2H, CH₂O), 3.31 (br q, J = 5.2 Hz, 2H, CH₂N), 2.42 (t, J = 2.4 Hz, 1H, CH), 1.44 [s, 9 H, C(CH₃)₃]; MS m/z 420.7 (MH⁺, 100%); HRMS (ESI) Calcd for C₂₀H₃₈NO₈ (MH⁺) m/z 420.2592, found 420.2590 (0.4 ppm).

5.1.14. Benzyl 4-(pyridine-3-ylcarbamoyl)benzylcarbamate (26)—Oxalyl chloride

(4.58 mL, 52.5 mmol) was added dropwise to a solution of 4-(benzyloxycarbonylamino)methylbenzoic acid **25**²⁰ (10.0 g, 35.0 mmol) and DMF (4 drops) in dry THF (150 mL), and the mixture stirred at 50 °C for 4 h. The solvent was evaporated and the residue dissolved in pyridine (80 mL). 3-Aminopyridine (3.62 g, 38.5 mmol) was added and the solution stirred at 20 °C for 48 h. Water (150 mL) was added, the mixture stirred for another 2 h, the precipitate filtered off, washed with water and dried to give the carbamate **26** (7.82 g, 62%) as a white solid: mp (EtOH) 207–210 °C; ¹H NMR δ 10.37 (s, 1H, NHCO), 8.92 (d, J = 2.3 Hz, 1H, H-2'), 8.31 (dd, J = 4.7, 1.5 Hz, 1H, H-6'), 8.18 (ddd, J = 8.3, 2.5, 1.5 Hz, 1H, H-4'), 7.93 (br d, J = 8.3 Hz, 2H, H-2, H-6), 7.89 (br t, J = 6.0 Hz, 1H, NHCO₂), 7.41 (br d, J = 8.3 Hz, 2H, H-3, H-5), 7.31–7.39 (m, 6 H, H-5', H-2'', H-3'', H-4'', H-5'', H-6''), 5.06 (s, 2H, CH₂O), 4.30 (d, J = 6.2 Hz, 2H, CH₂N). Anal. Calcd for C₂₁H₁₉N₃O₃: C, 69.79; H, 5.30; N, 11.63. Found: C, 69.60; H, 5.40; N, 11.63.

5.1.15. 4-(Aminomethyl)-*N*-(3-pyridinyl)benzamide dihydrobromide (27)—A

suspension of carbamate **26** (2.2 g, 6.09 mmol) in HBr/AcOH (30%, 30 mL) was stirred at 20 °C for 3 h. Et₂O (200 mL) was added, the mixture was stirred for another 30 min, the precipitate filtered off, washed with Et₂O and dried to give benzamide **27** (2.35 g, 99%) as a white solid: mp (EtOAc) 292–296 °C; ¹H NMR δ 11.06 (s, 1H, NHCO), 9.35 (d, J = 2.2 Hz, 1H, H-2'), 8.70 (ddd, J = 8.5, 2.2, 1.1 Hz, 1H, H-4'), 8.64 (br d, J = 5.4 Hz, 1H, H-6'), 8.31 (br s, 3H, NH₂·HBr), 8.09 (br d, J = 8.2 Hz, 2H, H-2, H-6), 7.96 (dd, J = 8.6, 5.4 Hz, 1H, H-5'), 7.67 (d, J = 8.4 Hz, 2H, H-3, H-5), 5.95 (br s, 1H, pyrN·HBr), 4.16 (q, J = 5.8 Hz, 2H, CH₂N). Anal. Calcd for C₁₃H₁₅Br₂N₃O: C, 40.13; H, 3.89; N, 10.80. Found: C, 39.99; H, 3.94; N, 10.36.

5.1.16. 4-((4-Iodophenylsulfonamido)methyl)-*N*-(pyridin-3-yl)benzamide (28)—

A mixture of amine **27** (727 mg, 3.2 mmol) and 4-iodobenzenesulfonyl chloride (970 mg, 3.2 mmol) in dry pyridine (10 mL) was stirred at 20 °C for 16 h. The solvent was evaporated

and the residue stirred in water (20 mL) for 1 h. The precipitate was filtered, washed with water (5 mL) and dried. The crude solid was purified by column chromatography, eluting with a gradient (0–20%) of MeOH/EtOAc, to give benzamide **28** (1.47 g, 93%) as a cream powder: mp (MeOH/EtOAc) 249–251 °C; ^1H NMR δ 10.36 (s, 1H, NHCO), 8.93 (d, J = 2.3 Hz, 1H, H-2'), 8.34 (br s, 1H, NHSO₂), 8.31 (dd, J = 4.7, 1.5 Hz, 1H, H-6'), 8.18 (ddd, J = 8.3, 2.5, 1.5 Hz, 1H, H-4'), 7.97 (ddd, J = 8.6, 2.2, 1.9 Hz, 2H, H-2'', H-6''), 7.90 (br d, J = 8.3 Hz, 2H, H-2, H-6), 7.56 (ddd, J = 8.6, 2.2, 1.9 Hz, 2H, H-3'', H-5''), 7.37–7.42 (m, 3H, H-3, H-5, H-5'), 4.09 (s, 2H, CH₂N); ^{13}C NMR δ 165.5, 144.5, 142.0, 141.6, 140.3, 138.1 (2), 135.8, 133.1, 128.2 (2), 127.7 (2), 127.5 (2), 127.3, 123.5, 100.3, 45.7; MS m/z 494.6 (MH⁺, 100%). Anal. Calcd for C₁₉H₁₆IN₃O₃S: C, 46.26; H, 3.27; N, 8.52. Found: C, 46.43; H, 3.30; N, 8.52.

5.1.17. *tert*-Butyl 21-{4-[(4-[(3-pyridinylamino)carbonyl]benzyl)amino)sulfonyl]phenyl}-3,6,9,12,15,18-hexaoxahenicos-20-yn-1-ylcarbamate (29)—PdCl₂(PPh₃)₂ (36 mg, 51 μmol) was added to a stirred, degassed solution of iodide **29** (250 mg, 510 μmol), acetylene **24** (320 mg, 770 μmol) and CuI (10 mg, 51 μmol) in Et₃N (3 mL) and DMF (3 mL), and the mixture was stirred in a sealed pressure vessel at 50 °C for 3 h. The mixture was cooled to 20 °C, diluted with EtOAc (150 mL) and washed with water (3 $\times$ 50 mL), washed with brine (50 mL) and dried. The solvent was evaporated and the residue purified by column chromatography, eluting with a gradient (0–5%) of MeOH/EtOAc, to give carbamate **29** (367 mg, 92%) as a tan oil: ^1H NMR (CDCl₃) δ 8.61 (br s, 1H, H-2'), 8.41 (br s, 1H, NHSO₂), 8.31 (d, J = 4.6 Hz, 1H, H-6'), 8.25 (ddd, J = 8.3, 2.4, 1.4 Hz, 1H, H-4'), 7.79–7.84 (m, 4H, H-2, H-6, H-2'', H-6''), 7.55 (dd, J = 8.6, 1.8 Hz, 2H, H-3'', H-5''), 7.28–7.34 (m, 3H, H-3, H-5, H-5'), 5.78 (br s, 1H, NHCO), 5.07 (br s, 1H, NHCO₂), 4.42 (s, 2H, CH₂O), 4.22 (br d, J = 6.0 Hz, 2H, CH₂N), 3.74–3.77 (m, 2H CH₂O), 3.68–3.71 (m, 2H CH₂O), 3.55–3.66 (m, 18H, 9 $\times$ CH₂O), 3.25 (br dd, J = 5.4, 5.2 Hz, 2H, CH₂N), 1.43 [s, 9 H, C(CH₃)₃]; MS m/z 786.0 (MH⁺, 100%); HRMS (ESI) Calcd for C₃₉H₅₃N₄O₁₁S (MH⁺) m/z 785.3426, Found 785.3410 (2.5 ppm).

5.1.18. 4-[(4-(21-Amino-4,7,10,13,16,19-hexaoxahenicos-1-yn-1-yl)phenyl)sulfonyl]amino)methyl]-*N*-(3-pyridinyl) benzamide (30)—A solution of carbamate **29** (360 mg, 0.46 mmol) in HCl saturated MeOH (10 mL) was stood at 20 °C for 16 h. The solvent was evaporated and the crude oil purified by preparative HPLC [gradient elution 5–55% of (90%MeCN/H₂O)/(0.02% v/v aqueous CF₃CO₂H)] to give the amine **30** as the trifluoroacetate salt (270 mg, 73%) as a brown gum: ^1H NMR δ 11.34 (s, 1H, NHCO), 9.42 (d, J = 2.2 Hz, 1H, H-2'), 8.88 (d, J = 8.8 Hz, 1H, H-4'), 8.64 (d, J = 4.9 Hz, 1H, H-4'), 8.47 (br s, 1H, NHSO₂), 8.04 (br d, J = 8.3 Hz, 2H, H-2, H-6), 7.96 (m, 4H, NH₂·CF₃CO₂H, H-5'), 7.82 (dd, J = 8.5, 1.8 Hz, 2H, H-2'', H-6''), 7.65 (dd, J = 8.5, 1.8 Hz, 2H, H-3'', H-5''), 7.44 (br d, J = 8.3 Hz, 2H, H-3, H-5), 4.43 (s, 2H, CH₂O), 4.12 (br d, J = 6.2 Hz, 2H, CH₂N), 3.51–3.65 (m, 22H, 11 $\times$ CH₂O), 2.95 (br q, J = 5.5 Hz, 2H, CH₂N); ^{13}C NMR δ 165.9, 142.5, 140.5, 138.6, 137.0, 134.7, 133.5, 132.0 (2), 131.9, 129.1, 128.1 (2), 127.7, 127.5 (2), 127.1, 126.8 (2), 125.8, 89.2, 84.3, 69.7 (3), 69.6 (2), 69.5, 68.8, 66.6, 58.0, 48.5, 45.7, 38.8; HRMS (ESI) Calcd for C₃₄H₄₅N₄O₉S (MH⁺) m/z 685.2902, Found 685.2898 (1.2 ppm).

5.1.19. *tert*-Butyl 21-{4-[(3-pyridinylamino)carbonyl]

benzyl}amino)sulfonyl]phenyl}-3,6,9,12,15,18-hexaoxahenicos-1-ylcarbamate (31)—A mixture of alkyne **29** (743 mg, 0.95 mmol) and 10% Pd/C (250 mg, 0.1 mmol) in absolute EtOH (30 mL) was stirred at 20 °C under of H₂ (60 psi) for 16 h. The mixture was filtered through diatomaceous earth, washed with EtOH (100 mL), and the solvent was evaporated. The residue was purified by column chromatography, eluting with a gradient (3–5%) of MeOH/DCM, to give carbamate **31** (650 mg, 87%) as a pale yellow oil: ¹H NMR δ 10.35 (s, 1H, CONH), 8.92 (d, *J* = 2.4 Hz, 1H, H-2'), 8.31 (dd, *J* = 4.7, 1.4 Hz, 1H, H-6'), 8.17–8.20 (m, 2H, NHSO₂, H-4'), 7.88 (br d, *J* = 8.3 Hz, 2H, H-2, H-6), 7.88 (br d, *J* = 8.3 Hz, 2H, H-2'', H-6''), 7.37–7.40 (m, 5 H, H-5', H-3, H-5, H-3'', H-5''), 6.69 (br s, 1H, NHCO₂), 4.08 (d, *J* = 5.0 Hz, 2H, CH₂N), 3.45–3.52 (m, 20 H, 10 × CH₂O), 3.37 (t, *J* = 6.2 Hz, 4H, H-3''', H-20'''), 3.05 (q, *J* = 6.0 Hz, 2H, H-21'''), 2.69 (t, *J* = 7.7 Hz, 2H, H-1'''), 1.77–1.84 (m, 2H, H-2'''), 1.37 [s, 9 H, C(CH₃)₃]; HRMS (ESI) Calcd for C₃₉H₅₆N₄O₁₁S (MH⁺) *m/z* 789.3739; found 789.3723 (1.6 ppm).

5.1.20. 4-[(4-(21-Amino-4,7,10,13,16,19-hexaoxahenicos-1-yl)phenyl)sulfonyl]amino) methyl]-*N*-(3-pyridinyl)benzamide (32)—

Trifluoroacetic acid (0.74 mL, 10 mmol) was added to a solution of carbamate **31** (313 mg, 0.4 mmol) in anhydrous DCM (5 mL) and the reaction mixture was stirred at 20 °C for 2 h. The solvent was evaporated and the residue was purified by column chromatography, eluting with 8% MeOH/DCM containing 1% aqueous NH₃, to give the amine **32** (195 mg, 71%) as a colourless oil: ¹H NMR δ 10.35 (br s, 1H, CONH), 8.92 (d, *J* = 2.2 Hz, 1H, H-2'), 8.31 (dd, *J* = 4.7, 1.4 Hz, 1H, H-6'), 8.18 (ddd, *J* = 8.3, 2.5, 1.5 Hz, 1H, H-4'), 7.88 (br d, *J* = 8.3 Hz, 2H, H-2, H-6), 7.70 (br d, *J* = 8.3 Hz, 2H, H-2'', H-6''), 7.37–7.40 (m, 5 H, H-5', H-3, H-5, H-3'', H-5''), 4.08 (s, 2H, CH₂NHSO₂), 3.45–3.52 (m, 20 H, 10 × CH₂O), 3.37 (t, *J* = 6.3 Hz, 2H, H-3'''), 3.34 (t, *J* = 5.8 Hz, 2H, H-20'''), 2.70 (t, *J* = 7.9 Hz, 2H, H-1'''), 2.63 (t, *J* = 5.7 Hz, 2H, H-21'''), 1.80 (tt, *J* = 6.4, 7.9 Hz, 2H, H-2'''), NHSO₂ and NH₂ not observed; ¹³C NMR δ 165.4, 146.6, 144.4, 141.9, 141.7, 138.0, 135.7, 132.8, 128.9 (2), 127.5 (2), 127.3 (2), 127.2, 126.4 (2), 123.3, 72.2, 69.69 (2), 69.66 (4), 69.62 (2), 69.4, 69.3, 69.1, 45.6, 40.9, 31.3, 30.4; HRMS (ESI) Calcd for C₃₄H₄₈N₄O₉S (MH⁺) *m/z* 689.3215; Found 389.3224 (–1.0 ppm).

5.1.21. 4-(Aminomethyl)-*N*-phenylbenzamide hydrobromide (34)—Oxalyl

chloride (0.92 mL, 10.5 mmol) was added dropwise to a stirred suspension of benzoic acid **25**²⁰ (2.0 g, 7.0 mmol) and DMF (3 drops) in dry THF (50 mL) and the solution was stirred at 20 °C for 4 h. The solvent was evaporated and the residue dissolved in pyridine (10 mL). Aniline (0.70 mL, 7.7 mmol) was added and the solution stirred at 20 °C for 16 h. The solvent was evaporated and the residue suspended in ice/water (100 mL) for 1 h. The precipitate was filtered, washed with water (5 mL) and dried to give crude benzyl 4-(anilinocarbonyl)benzyl carbamate (**33**) (1.45 g, 57%) as a white powder: mp (H₂O) 276–279 °C; ¹H NMR δ 10.16 (s, 1H, CONH), 7.86–7.93 (m, 3H, NHC(=O)₂, H_{aryl}), 7.77 (d, *J* = 8.6 Hz, 2H, H_{aryl}), 7.30–7.41 (m, 9H, H_{aryl}), 7.10 (br t, *J* = 7.3 Hz, 1H_{aryl}), 4.14 (br q, *J* = 5.4 Hz, 2H, CH₂N). A suspension of carbamate **33** (1.45 g, 4.0 mmol) in HBr/AcOH (30%, 30 mL) was stirred at 20 °C for 6 h. Et₂O (150 mL) was added, the mixture was stirred at 5 °C for 30 min, the precipitate filtered off, washed with Et₂O and dried to give benzamide

hydrobromide **34** (1.15 g, 93%) as a white solid: mp (Et₂O) 276–279 °C; ¹H NMR δ 10.25 (s, 1H, CONH), 8.27 (br s, 3H, NH₂·HBr), 8.30 (br d, *J* = 8.2 Hz, 2H, H-2, H-6), 7.79 (dd, *J* = 8.5, 7.5 Hz, 2H, H-2', H-6'), 7.61 (d, *J* = 8.4 Hz, 2H, H-3, H-5), 7.36 (dd, *J* = 8.5, 7.5 Hz, 2H, H-3', H-5'), 7.11 (br t, *J* = 7.5 Hz, 1H, H-4'), 4.14 (q, *J* = 5.4 Hz, 2H, CH₂N). Anal. Calcd for C₁₄H₁₅BrN₂O: C, 54.74; H, 4.92; N, 9.12. Found: C, 54.73; H, 4.76; N, 8.96.

5.1.22. 4-([4-(4-iodophenyl)sulfonyl]amino)methyl)-*N*-phenylbenzamide (35)—A mixture of amine **34** (408 mg, 1.8 mmol) and 4-iodobenzenesulfonyl chloride (551 mg, 1.8 mmol) in dry pyridine (10 mL) was stirred at 20 °C for 16 h. The solvent was evaporated and the residue stirred in water (20 mL) for 1 h. The precipitate was filtered, washed with water (5 mL) and dried, to give benzamide **35** (710 g, 80%) as a white powder: mp (EtOAc) 252–254 °C; ¹H NMR δ 10.15 (s, 1H, CONH), 8.32 (br t, *J* = 6.2 Hz, 1H, NHSO₂), 7.97 (ddd, *J* = 8.6, 2.2, 1.8 Hz, 2H, H-3'', H-5''), 7.88 (d, *J* = 8.3 Hz, 2H, H-2, H-6), 7.77 (dd, *J* = 8.4, 1.0 Hz, 2H, H-2', H-6'), 7.56 (ddd, *J* = 8.6, 2.2, 1.8 Hz, 2H, H-2'', H-6''), 7.38–7.40 (m, 4H, H-3, H-5, H-3', H-5'), 7.10 (tt, *J* = 7.4, 1.0 Hz, 1H, H-4'), 4.08 (d, *J* = 6.3 Hz, 2H, CH₂N); ¹³C NMR δ 165.1, 141.2, 140.3, 139.1, 138.0 (2), 133.7, 128.5 (2), 128.2 (2), 127.6 (2), 127.4 (2), 123.6, 120.4 (2), 100.3, 45.7; MS *m/z* 493.6 (MH⁺, 100%). Anal. Calcd for C₂₀H₁₇IN₂O₃S: C, 48.79; H, 3.48; N, 5.69. Found: C, 49.06; H, 3.56; N, 5.84.

5.1.23. *tert*-Butyl 21-[4-([4-(anilincarbonyl)benzyl]amino)sulfonyl]phenyl]-3,6,9,12,15,18-hexaaxahenicos-20-yn-1-ylcarbamate (36)—PdCl₂(PPh₃)₂ (85 mg, 0.12 mmol) was added to a stirred, degassed solution of iodide **35** (600 mg, 1.22 mmol), acetylene **19** (765 mg, 1.82 mmol) and CuI (23 mg, 0.12 mmol) in Et₃N (5 mL) and DMF (5 mL), and the mixture was stirred in a sealed pressure vessel at 50 °C for 2 h. It was cooled to 20 °C, diluted with EtOAc (200 mL), washed with water (3 × 50 mL), washed with brine (50 mL) and dried. The solvent was evaporated and the residue purified by column chromatography, eluting with a gradient (0–5%) of MeOH/DCM, to give carbamate **36** (1.0 g, 100%) as a tan oil: ¹H NMR δ 10.15 (s, 1H, NHCO), 8.34 (br s, 1H, NHSO₂), 7.88 (br d, *J* = 8.3 Hz, 2H, H-3'', H-5''), 7.80 (br d, *J* = 8.5 Hz, 2H, H-3', H-5'), 7.76 (br d, *J* = 7.6 Hz, 2H, H-2'', H-6''), 7.65 (br d, *J* = 8.5 Hz, 2H, H-2', H-6'), 7.38 (br d, *J* = 8.5 Hz, 2H, H-2'', H-6''), 7.34 (br d, *J* = 8.3 Hz, 2H, H-3'', H-5''), 7.10 (br t, *J* = 7.4 Hz, 1H, H-4''), 6.70 (br s, 1H, NHCO₂), 4.43 (s, 2H, C≡CCH₂O), 4.10 (s, 2H, CH₂NHCO₂), 3.62–3.65 (m, 2H, CH₂O), 3.56–3.59 (m, 2H, CH₂O), 3.49–3.53 (m, 16 H, 8 × CH₂O), 3.37 (br t, *J* = 6.1 Hz, 2H, H-20), 3.06 (br q, *J* = 5.9 Hz, 2H, H-21), 1.37 [s, 9H, C(CH₃)₃]; HRMS (ESI) Calcd for C₄₀H₅₄N₃O₁₁S (MH⁺) *m/z* 784.3474; Found 784.3460.

5.1.24. *tert*-Butyl 21-[4-([4-(anilincarbonyl)benzyl]amino)sulfonyl]phenyl]-3,6,9,12,15,18-hexaaxahenicos-1-ylcarbamate (37)—A mixture of carbamate **36** (923 mg, 1.17 mmol) and 10% Pd/C (300 mg, 0.12 mmol) in absolute EtOH (50 mL) was stirred at 20 °C under H₂ (60 psi) for 16 h. The mixture was filtered through a pad of diatomaceous earth, washed with EtOH (200 mL), the solvent was evaporated and the residue was purified by column chromatography, eluting with a gradient (0–5%) of MeOH/DCM to give carbamate **37** (742 mg, 80%) as a tan oil: ¹H NMR δ 10.14

(s, 1H, NHCO), 7.86 (br d, $J = 8.3$ Hz, 2H, H-3'', H-5''), 7.76 (br dd, $J = 8.7, 1.0$ Hz, 2H, H-3', H-5'), 7.71 (br d, $J = 8.3$ Hz, 2H, H-2''', H-6'''), 7.32–7.40 (m, 6 H, H-2', H-6', H-2'', H-6'', H-3''', H-5'''), 7.16 (t, $J = 6.2$ Hz, 1H, NHC(CH₃)₃), 7.09 (br t, $J = 7.4$ Hz, 1H, H-4'''), 6.69 [br s, 1H, NHC(CH₃)₃], 4.07 (d, $J = 5.9$ Hz, 2H, CH₂NHSO₂), 3.45–3.52 (m, 20 H, 10 × CH₂O), 3.37 (br t, $J = 6.2$ Hz, 4H, H-19, H-2), 3.05 (br q, $J = 5.9$ Hz, 2H, H-1), 2.69 (br t, $J = 7.9$ Hz, 2H, H-21), 1.80 (tt, $J = 7.9, 6.3$ Hz, 2H, H-20), 1.37 [s, 9 H, C(CH₃)₃]; HRMS (ESI) Calcd for C₄₀H₅₈N₃O₁₁S (MH⁺) m/z : 788.3787; Found 788.3796.

5.1.25. 4-[[[4-(21-Amino-4,7,10,13,16,19-hexaoxahenicos-1-yl)phenyl]sulfonyl]amino)methyl]-N-phenylbenzamide (38)—A solution of

carbamate **37** (245 mg, 0.31 mmol) in anhydrous DCM (5 mL) was treated with TFA (0.6 mL, 7.8 mmol) and the reaction mixture was stirred at 20 °C for 2 h. The solvent was evaporated and the residue was purified by column chromatography, eluting with a gradient (92:7:0.8–92:8.5:1) of DCM/MeOH/aq NH₃ to give the amine **38** (164 mg, 77%) as a pale yellow oil: ¹H NMR δ 10.14 (s, 1H, NHCO), 7.86 (br d, $J = 8.3$ Hz, 2H, H-2, H-6), 7.76 (br dd, $J = 8.6, 1.0$ Hz, 2H, H-2'', H-6''), 7.71 (br d, $J = 8.3$ Hz, 2H, H-2', H-6'), 7.32–7.41 (m, 6 H, H-3, H-5, H-3', H-5', H-3'', H-5''), 7.10 (br t, $J = 7.4$ Hz, 1H, H-4'), 4.07 (s, 2H, CH₂NHSO₂), 3.46–3.52 (m, 20H, 10 × CH₂O), 3.37 (t, $J = 6.3$ Hz, 2H, H-3'''), 3.35 (t, $J = 5.8$ Hz, 2H, H-20'''), 2.69 (t, $J = 8.0$ Hz, 2H, H-1'''), 2.64 (br s, 2H, H-21'''), 1.80 (tt, $J = 7.9, 6.3$ Hz, 2H, H-2'''), NHC(CH₃)₃ and NH₂ not observed; ¹³C NMR δ 165.0, 146.6, 141.3, 139.0, 138.0, 133.5, 128.9 (2), 128.4 (2), 127.4 (2), 127.2 (2), 126.4 (2), 123.5, 120.2 (2), 69.7 (9), 69.6, 69.4, 69.3, 69.1, 45.6, 31.3, 30.4; HRMS (ESI) Calcd for C₃₅H₅₀N₃O₉S (MH⁺) m/z : 688.3262; Found: 688.3252.

5.1.26. Preparation of affinity reagents—A slurry of Affi-Gel 10 (5 mL) was washed with cold *i*PrOH (5 × 5 mL) in a sintered funnel and was transferred to a sealed pressure vessel. A solution of amine **32** or **38** (61 mg, 0.08 mmol) in MeOH (5 mL) was added, followed by *i*Pr₂OEt (0.14 mL, 0.8 mmol). The sealed tube was placed on a rotary shaker and gently agitated, monitoring the reaction by HPLC. After 6 h, ethanolamine (9 μL, 0.15 mmol) was added and the mixture was agitated for another 16 h. The mixture was filtered, and the gel washed with MeOH (5 × 5 mL) and *i*PrOH (5 × 5 mL), to give an off-white slurry which was used for affinity chromatography experiments.

5.2. Molecular modeling

5.2.1. Molecular modeling for PAT chemotype—A base CoMFA 3D-QSAR model was created as previously described.¹⁴

5.2.2. Molecular modeling for PPB chemotype—The likely protonation state of the test compounds at pH 7.4 was predicted using Filter (OpenEye Scientific Software, Santa Fe, NM; <http://www.eyesopen.com/>), followed by conformer generation using OMEGA2 (version 3.2 OpenEye Scientific Software, Santa Fe, NM; <http://www.eyesopen.com/>). The MMFF94s forcefield was used for model construction and the dielectric set at 80. Strain energies were calculated during conformer generation using the MMFF94s forcefield and the conformer energy window was set at 20 kcal/mol, with the RMS between conformations set at 0.8, only one conformer was kept. All other settings were left as default. GOLD³⁰ was

then used to dock the lowest energy conformer into a 20 Å cavity that covered the internal channel of a GLUT1 homology model (PDB entry 1SUK).¹⁷ The Goldscore scoring function was used at maximum search efficiency, and 20 poses separated by a minimum RMSD of 2 Å were kept, all other conditions were kept at default settings. Predicted binding poses were subsequently refined by energy minimization using the Tripos force field with Gastieger–Huckel charge set. A minimisation protocol was used that included 1000 iterations of Steep Descents method followed by the Conjugate Gradient method until convergence with the cutoff set at 0.05 kcal/mol. The ligand and all protein atoms within 8 Å were allowed to move, while an additional 8 Å was immobile but still considered in the calculation. A set of ‘active’ compounds that represented small and large substitutions on the terminal benzene (S1–S6: RCC4 IC₅₀ <1 μM) (Table S1, Supplementary data) were used in docking studies.

5.3. Cell viability assays

RCC4 parental cells and RCC4 cells with VHL reintroduced (RCC4/VHL),² were maintained in DMEM supplemented with 10% FCS. Compounds were evaluated in a XTT growth inhibition assay (as IC₅₀: the drug concentration required to inhibit cell growth by 50%). Five thousand cells were plated in 96-well plates. The following day vehicle (DMSO) or drug was added by serial dilution from a top concentration of 40 μM in triplicate. Four days later the media was aspirated, 2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2*H*-tetrazolium-5-carboxanilide (XTT) solution (0.3 mg/mL) (Sigma), 2.65 mg/ml *N*-methyl dibenzopyrazine methyl sulfate (Sigma) in phenol red-free media was added, and the plates were incubated at 37 °C for 1–2 h. Metabolism of XTT was quantified by measuring the absorbance at 450 nm. IC₅₀ values were calculated using interpolation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank Drs. Shannon Black and Sisira Kumara for technical assistance and acknowledge the Association for International Cancer Research 10-0042 (M.B.), the Maurice Wilkins Centre for Biodiscovery (M.P.H., J.U.F.), US NCI-CA-82566 (A.J.G., M.P.H.), and NCI-CA-123823 (D.A.C.).

Abbreviations

BOC	<i>tert</i> -butoxycarbonyl
DCM	dichloromethane
DMF	dimethylformamide
HTS	high throughput screening
PAT	pyridylanilino thiazole
PPB	pyridylphenylsulfonyl benzamides

PEG	polyethylene glycol
RCC	renal cell carcinoma
SAR	structure–activity relationship
TBTA	tris-(benzyltriazolyl)amine
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TMS	trimethylsilyl

References

1. Kaelin WG Jr. *Nat. Rev. Cancer.* 2005; 5:689. [PubMed: 16110319]
2. Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ. *Cancer. Res.* 2007; 67:5896. [PubMed: 17575159]
3. Chan DA, Giaccia AJ. *Cell Cycle.* 2008; 7:2987. [PubMed: 18818511]
4. Turcotte S, Sutphin PD, Chan DA, Hay MP, Denny WA, Giaccia AJ. *Cancer Cell.* 2008; 14:90. [PubMed: 18598947]
5. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi J-T, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ. *Sci. Trans. Med.* 2011; 3:94ra70.
6. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. *CA-Cancer. J. Clin.* 2007; 7:43.
7. Jonash E, Futreal AP, Davis IA, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. *Mol. Cancer. Res.* 2012; 10:859. [PubMed: 22638109]
8. Frew IJ, Krek W. *Sci. Signal.* 2008; 1:30.
9. Kaelin WG Jr. *Nat. Rev. Cancer.* 2008; 8:865. [PubMed: 18923434]
10. Wilson WR, Hay MP. *Nat. Rev. Cancer.* 2011; 11:393. [PubMed: 21606941]
11. Kim WY, Kaelin WG Jr. *J. Clin. Oncol.* 2004; 22:4991. [PubMed: 15611513]
12. Sato S, Murata A, Shirakawa T, Uesugi M. *Chem. Biol.* 2010; 17:616. [PubMed: 20609411]
13. Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ, Denny WA. *J. Med. Chem.* 2010; 53:787. [PubMed: 19994864]
14. Bonnet M, Flanagan JU, Chan DA, Lai EW, Nguyen P, Giaccia AJ, Denny WA. *Bioorg. Med. Chem.* 2011; 19:3347. [PubMed: 21561782]
15. Kolb HC, Finn MG, Sharpless KB. *Angew. Chem., Int. Ed.* 2001; 40:2004.
16. Sutphin, PD., Chan, DA., Turcotte, S., Denny, WA., Hay, MP., Giddens, AC., Bonnet, M., Giaccia, AJ. PCT Patent Appl. WO. 2,011,011,514 A1. Jan 27. 2011
17. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J. *Biophys. J.* 2004; 87:2990. [PubMed: 15326030]
18. Chen TR, Hilgraf R, Sharpless BK, Fokin V. *Org. Lett.* 2004; 6:2853. [PubMed: 15330631]
19. Larsson A, Angbrant J, Ekeröth J, Mansson P, Liedberg B. *Sens. Activators, B.* 2006; 13:730.
20. Loge C, Wallez V, Scalbert E, Cario-Tourmaniantz C, Loirand G, Pacaud P, Lesieur DJ. *Enzyme Inhib. Med. Chem.* 2002; 17:381.
21. Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD. *Mol. Cancer Ther.* 2008; 7:3546. [PubMed: 19001437]
22. Brockmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascual JM, Kuang K, Yang H, Ma L, Kranz-Eble P, Fischbarg J, Hanefeld F, De Vivo DC. *Ann. Neurol.* 2001; 50:476. [PubMed: 11603379]

23. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X. *Mol. Cancer Ther.* 2012; 11:1672. [PubMed: 22689530]
24. Garcia JC, Strube M, Leingang K, Keller K, Mueckler MM. *J. Biol. Chem.* 1992; 267:7770. [PubMed: 1560011]
25. Liu Y, Zhang W, Cao Y, Bergmeier S, Chen X. *Cancer Lett.* 2010; 298:176. [PubMed: 20678861]
26. Zhang W, Liu Y, Chen X, Bergmeier SC. *Bioorg. Med. Chem. Lett.* 2010; 20:2191. [PubMed: 20194024]
27. Wang D, Chu PC, Yang C-N, Yan R, Chuang Y-C, Kulp SK, Chen C-S. *J. Med. Chem.* 2012; 55:3827. [PubMed: 22468970]
28. Teicher BA, Linehan WM, Helman LJ. *Cancer. Res.* 2012; 18:5537.
29. Kaelin WG Jr, Thompson CB. *Nature.* 2010:465–562.
30. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. *Proteins.* 2003; 52:609. [PubMed: 12910460]

Figure 1.
PAT and PPB chemotypes identified from RCC HTS.

Figure 2.
CoMFA model 3D-QSAR conformer model relating PAT conformation to cytotoxicity.
Electrostatic fields are contoured at 80% favored (blue) and 20% disfavored (red). Steric
fields are contoured at 80% favored (green) and 20% disfavored (yellow).

Figure 3.

A representation of PPB **S3** (white ball and stick) and fasentin (blue stick) modelled in the central transport channel of GLUT-1. Possible interactions with Trp412 and Arg126 are shown.

Scheme 1.

Reagents and conditions: (a) (i) TMS-acetylene, PdCl₂(PPh₃)₂, CuI, NEt₃, DMF, 50 °C; (ii) K₂CO₃, THF/MeOH, 20 °C; (b) azide, CuSO₄·5H₂O, Na ascorbate, DCM/H₂O/EtOH, 20 °C; (c) TFA/DCM, 20 °C; (d) EtI, DMF, 20 °C.

Scheme 2.

Reagents and conditions: (a) (i) TMS-acetylene, $\text{PdCl}_2(\text{PPh}_3)_2$, CuI , NEt_3 , DMF, 50 °C; (ii) K_2CO_3 , THF/MeOH, 20 °C; (b) CuI , NaI , $\text{MeNH}(\text{CH}_2)_2\text{NHMe}$, dioxane, 110 °C; (c) $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, Na ascorbate, DCM/ H_2O /DMF, 20 °C, 20 h; (d) azide, $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$, Na ascorbate, TBTA, DCM/ H_2O /DMF, 60 °C, 20 h; (e) EtI , DMF, 20 °C.

Scheme 3.

Reagents and conditions: (a) MsCl, Ag₂O, DCM; (b) NaN₃, DMF; (c) H₂ (60 psi), Pd/C, EtOH; (d) BOC₂O, DCM; (e) MsCl, Et₃N, DCM; (f) HCl/MeOH; (g) NaH, propargyl bromide, *n*Bu₄N⁺I⁻, THF.

Scheme 4.

Reagents and conditions: (a) (COCl)₂, DMF, THF, 50 °C, then 3-aminopyridine or aniline;
 (b) HBr, HOAc, 20 °C; (c) 4-IPhSO₂Cl, pyridine, 20 °C (d) PdCl₂(PPh₃)₂, **24**, CuI, Et₃N, DMF, 50 °C; (e) HCl, MeOH, 20 °C; (f) H₂, Pd/C, EtOH, 20 °C; (g) TFA, DCM, 20 °C.

Table 1IC₅₀ values and selectivity ratios in Renal Cell Carcinoma cells

No	RCC4 IC ₅₀ (μM)	RCC4/VHL IC ₅₀ (μM)	Ratio ^a
1 ^b	2.1	40	19
2	0.16	>40 ^c	>250
7	1.7	2.6	1.5
8	>40	>40	ND
11	>40	>40	ND
16	2.9	3.9	1.3
19	>40	>40	ND
30	5.8	>40	>7
32	7.9	>40	>5
38	>40	>40	ND

^aRatio = IC₅₀ (RCC4/VHL)/IC₅₀ (RCC4).^bData from Ref. 15.^cSolubility prevented determination of IC₅₀ values.